Ani Pharmaceuticals (ANIP) Free Cash Flow (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Free Cash Flow data on file, last reported at $52.3 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 53.97% year-over-year to $52.3 million; the trailing twelve-month figure through Mar 2026 stood at $202.5 million (up 151.84% YoY), and the FY2025 full-year result was $184.2 million, up 190.09% from the prior year.
• Free Cash Flow rose to $52.3 million in Q1 2026, from $41.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $70.3 million in Q2 2025 to a low of -$19.2 million in Q1 2022.
• A 5-year average of $22.8 million and a median of $19.1 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow tumbled 1638.06% in 2022 and jumped 15080.8% in 2025, its largest moves.
• Tracing ANIP's Free Cash Flow over 5 years: stood at -$4.6 million in 2022, then surged by 1060.82% to $44.7 million in 2023, then plunged by 34.68% to $29.2 million in 2024, then surged by 43.65% to $41.9 million in 2025, then rose by 24.8% to $52.3 million in 2026.
• Business Quant data shows ANIP's Free Cash Flow at $52.3 million in Q1 2026, $41.9 million in Q4 2025, and $38.0 million in Q3 2025.